NBRV News and Press, Nabriva Therapeutics plc From 03/29/22

The commercial-stage pharma company, Nabriva Therapeutics (NASDAQ:NBRV) is trading ~9% lower in the post-market Tuesday after announcing its 4Q 2021 results, which indicated a slowdown in its growth momentum. Revenue for the quarter more than tripled to $9.3M, backed by $8.4M in net...

Nabriva Therapeutics press release (NASDAQ:NBRV): Q4 GAAP EPS of -$0.24. Revenue of $9.26M (+276.4% Y/Y). Shares -4%. "We remain focused on driving growth of SIVEXTRO, educating the medical community on the benefits of XENLETA, and expanding XENLETA geographically as we continue to assess par...

-Total revenue of $9.3 million driven by continued SIVEXTRO prescription growth- -Net product sales increased 8% sequentially in Q4 2021 versus Q3 2021- -Cash runway extended well into Q4 2022- -Conference call today at 4:30 p.m. Eastern Time- DUBLIN, Irela...

Nabriva Therapeutics (NASDAQ:NBRV) is scheduled to announce Q4 earnings results on Tuesday, March 29th, after market close. The consensus EPS Estimate is -$0.19 (+82.9% Y/Y) and the consensus Revenue Estimate is $10.1M (+310.6% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward re...

AMPE, AREC, CALM, CHWY, CRMD, CWBR, CWCO, HTGM, INFI, OTCQB:LQMT, LULU, MLKN, MOTS, MU, MVST, NBRV, NBY, OTC:OIBZQ, OPGN, PAVM, PRGS, PVH, RH, SNDL, SPWH, SUNL, VRNT, ZVO For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Tuesd...

DUBLIN, Ireland and FORT WASHINGTON, Pa., March 15, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will re...

— Meeting to Reconvene on March 24, 2022 — DUBLIN, Ireland and FORT WASHINGTON, Pa., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infecti...

— Meeting to Reconvene on January 18, 2022 — DUBLIN, Ireland and FORT WASHINGTON, Pa., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective a...

-SIVEXTRO ® (tedizolid phosphate) remains on track for return to historical peak sales by mid-2022- -XENLETA ® (lefamulin) Phase I Cystic Fibrosis (CF) trial on track to enroll first patient in Q122- -Cash resources of $47.7 million as o...

DUBLIN, Ireland and FORT WASHINGTON, Pa., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it int...